Drug intelligence / Profile preview

PfRAS

Development stage: Unknown
Lead developer: Sanaria
Modality: Vaccines & Immunotherapeutics
Administration: Mosquito Bite

Overview

PfRAS (Plasmodium falciparum Radiation-Attenuated Sporozoites) is a vaccine designed to induce protective immunity against malaria. It consists of Plasmodium falciparum sporozoites that have been attenuated through radiation, rendering them unable to replicate in the host. Administered via mosquito bite, PfRAS aims to stimulate a robust immune response, primarily involving CD8+ T cells, which recognize parasite-derived peptides on infected hepatocytes, thereby preventing the development of malaria. Clinical trials have investigated its safety, tolerability, and efficacy in inducing sterilizing immunity.

Other names: Plasmodium falciparum Sporozoites (PfRAS)radiation-attenuated Plasmodium falciparum sporozoites (PfRAS)P. falciparum RAS-immunized (PfRAS)

Targets

CSP (Circumsporozoite protein)

Beyond the preview

Go deeper on PfRAS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PfRAS.

Explore the full profile